Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RLAY 
Relay Therapeutics Inc (RLAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RLAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -32.88% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 418.72M USD | Price to earnings Ratio - | 1Y Target Price 19.64 |
Price to earnings Ratio - | 1Y Target Price 19.64 | ||
Volume (30-day avg) 2427554 | Beta 1.65 | 52 Weeks Range 2.38 - 10.72 | Updated Date 04/1/2025 |
52 Weeks Range 2.38 - 10.72 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3854.04% |
Management Effectiveness
Return on Assets (TTM) -28.11% | Return on Equity (TTM) -44.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -290368975 | Price to Sales(TTM) 41.84 |
Enterprise Value -290368975 | Price to Sales(TTM) 41.84 | ||
Enterprise Value to Revenue 18.17 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 169522000 | Shares Floating 119706158 |
Shares Outstanding 169522000 | Shares Floating 119706158 | ||
Percent Insiders 1.8 | Percent Institutions 104.13 |
Analyst Ratings
Rating 4.46 | Target Price 21.45 | Buy 5 | Strong Buy 7 |
Buy 5 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Relay Therapeutics Inc
Company Overview
History and Background
Relay Therapeutics, Inc. was founded in 2016. It is a clinical-stage precision medicine company committed to discovering and developing new medicines that will dramatically improve the lives of patients with cancer and other diseases.
Core Business Areas
- Discovery and Development of Therapies: Relay Therapeutics focuses on developing therapies that target specific protein mutations and dysfunctions, particularly in oncology.
Leadership and Structure
The leadership team includes key executives in research and development, finance, and commercial operations. The company has a scientific advisory board of experts. Organizational structure is typical for a biotechnology company focused on drug development.
Top Products and Market Share
Key Offerings
- RLY-4008 (FGFR2 inhibitor): A selective FGFR2 inhibitor being developed for cholangiocarcinoma and other FGFR2-altered cancers. Currently in clinical trials. Market share data is not yet available as the product is not yet approved. Competitors in FGFR inhibitor space include Incyte(PEMAZYRE).
- RLY-2608 (PI3Ku03b1 inhibitor): A PI3Ku03b1 inhibitor being developed for PIK3CA-mutant cancers. Currently in clinical trials. Market share data is not yet available as the product is not yet approved. Competitors in PI3K inhibitor space include Novartis(PIQRAY).
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Precision medicine is a growing area.
Positioning
Relay Therapeutics is positioned as a precision medicine company focused on developing targeted therapies. Its competitive advantage lies in its Dynamo platform that allows drug target development.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is significant. Relay Therapeutics is targeting specific, genetically defined subsets of cancer, which provides a smaller, yet valuable, part of the overall oncology TAM. Estimates vary widely, but the overall oncology market is in the hundreds of billions of USD annually. Relay therapeutics is specifically targeting smaller addressable markets that have been traditionally hard to drug.
Upturn SWOT Analysis
Strengths
- Proprietary Dynamo platform
- Strong research and development capabilities
- Experienced leadership team
- Focus on precision medicine
Weaknesses
- Reliance on successful clinical trial outcomes
- High cash burn rate
- Dependence on securing regulatory approvals
- No currently marketed products
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Advancements in genomic sequencing and diagnostics
- Potential for breakthrough therapies
Threats
- Clinical trial failures
- Competition from other pharmaceutical and biotechnology companies
- Changes in regulatory landscape
- Economic downturns
Competitors and Market Share
Key Competitors
- ARRY
- INCY
- NVS
Competitive Landscape
Relay Therapeutics competes with established pharmaceutical and biotechnology companies in the oncology space. Its advantage lies in its Dynamo platform and focus on precision medicine, but faces risk due to other competitors working on similar targets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Relay Therapeutics has grown as a company in terms of clinical programs. They have expanded their research and development efforts.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals for its drug candidates. Analyst estimates are based on these factors.
Recent Initiatives: Initiatives include advancing RLY-4008 and RLY-2608 through clinical trials, expanding its pipeline with new drug candidates, and exploring potential partnerships.
Summary
Relay Therapeutics is a precision medicine company with a promising platform. The company is pre-revenue and relies on successful clinical trial outcomes to create revenue. They have a solid cash position. Investors need to monitor clinical trial results and regulatory developments as these directly influence share price.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
INCY
Incyte Corporation
INCY
Incyte Corporation
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Relay Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and due diligence. Market share data is not available for companies that have pre-market products.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relay Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-07-16 | CEO, President & Director Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 261 | Website https://www.relaytx.com |
Full time employees 261 | Website https://www.relaytx.com | ||
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor which is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins for NRAS-mutated solid tumors; RLY-1013, an oral, potent, selective, bifunctional protein degrader of estrogen receptor alpha; RLY-2139, an oral, small molecule, potent, and selective inhibitor of Cyclin-dependent kinases (CDK2) that spares other CDKs. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. Further, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer for the development of RLY-2608. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.